Skip to main content

December 13, 2019


My primary clinical and research interest focus is on sickle cell disease. Past efforts have focused on improving the care of patients with sickle cell disease through quality improvement initiatives such as improving time to antibiotics in children with SCD presenting with fevers as well as improving delivery of analgesia in the ED setting. As a Hispanic female physician, it is an honor and, indeed part of my mission as an academic physician, to serve as a mentor and sponsor to trainees, particularly those from backgrounds historically marginalized, underserved and underrepresented in medicine.

Melissa Caughey

December 12, 2019


I studied the epidemiology of sickle cell disease during my doctoral training and am currently an Assistant Professor in biomedical engineering. I am developing a wearable device to monitor hydration status in individuals with sickle cell disease, and a contact-free assay to evaluate stored red blood cell quality prior to transfusion. I have coauthored 3 manuscripts with Dr. Nigel Key, who also served on my dissertation committee. I have also been mentored by Dr. Enrico Novelli at the University of Pittsburgh, where I participated as a research scholar in the NHLBI-funded Intensive Training in Hematology program. For the past 4 years, I have served as an abstract reviewer for the Foundation for Sickle Cell Disease Research Symposium.

Photo of Patrick Ellsworth

December 12, 2019


Assistant Professor, Research interests: I am interested in the interaction between endothelium and coagulation proteins as well as blood cells. I have recently presented data showing an increase of factor Xa generation on endothelium in the presence of emicizumab and factor IXa. I am active in investigating the mechanism of thrombosis and thrombotic microangiopathy in the use of emicizumab and have an interest in improving the treatment of breakthrough bleeding in patients on emicizumab. I am more generally interested in the development of systems that can shed light on the mechanisms and complications of emerging, non-factor therapies for hemophilia.

December 12, 2019


Research Interests My research interest focuses on the mechanisms of cancer-associated thrombosis and bleeding. My primary interest is mechanisms of pancreatic cancer-associated venous thrombosis because pancreatic cancer has one of the highest rates of venous thrombosis. I have found that tumor-derived tissue factor positive extracellular vesicles, neutrophils and neutrophil extracellular traps, and plasminogen activator inhibitor-1 independently contribute to venous thrombosis in mouse models of pancreatic cancer.

December 5, 2019


I am the Director of the Francis Owen Blood Research Laboratory (FOBRL), the mission of which is to reduce human and animal suffering from bleeding, thrombosis and atherosclerosis by the study of unique, genetically-determined animal models of these diseases. The FOBRL was established in 1960 by Dr. Kenneth M. Brinkhous and has provided work and study opportunities for many undergraduate, M.D., D.V.M. and Ph.D. students, post-doctoral students, and faculty at UNC and from several institutions worldwide.

December 4, 2019


My lab develops microfluidic models of the blood and lymphatic vasculature for basic science and translational purposes. Specific projects relevant to the Blood Research Center are: 1) Understanding the role of Notch receptor signaling in vascular endothelial adherens junction assembly and stability; 2) A nascent collaboration with Dr. Prabir Roy-Chaudhury at the UNC Kidney center to screen patient plasma in microfluidic models of the vasculature to predict risk of cardiovascular complications in kidney disease.

Samuel Wilson

December 2, 2019


As individuals with sickle cell disease (SCD) are living longer, there is a growing adolescent and young adult population with unique manifestations of SCD that are poorly understand. My research interests are broadly in understanding clinical outcomes in SCD management, characterizing individuals at greater risk for complications and in improving guideline-based care of those with SCD, especially in the diagnosis and management of iron overload. I am joining the non-malignant hematology faculty at UNC and am interested in pursing research in non-malignant hematology. As a member of the BRC, I will have the support and opportunity to continue my research pursuits.